TY - JOUR
T1 - Lack of pharmacologic tolerance and rebound angina pectoris during twice-daily therapy with isosorbide-5-mononitrate
AU - Thadani, Udho
AU - Maranda, Claude R.
AU - Amsterdam, Ezra A
AU - Spaccavento, Leo
AU - Friedman, Richard G.
AU - Chernoff, Robert
AU - Zellner, Stephen
AU - Gorwit, Jeffrey
AU - Hinderaker, Paul H.
PY - 1994/3/1
Y1 - 1994/3/1
N2 - ■ Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. ■ Design: Multicenter, placebo-controlled, parallelgroup, double-blind, randomized study. ■ Setting: Four university teaching hospitals and five private cardiology outpatient clinics. ■ Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. ■ Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received singleblind placebo for .1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. ■ Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. ■ Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group. ■ Conclusion: lsosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.
AB - ■ Objective: To determine whether isosorbide-5-mononitrate (IS-5-MN), an active metabolite of isosorbide dinitrate, when given twice daily (in the morning and 7 hours later), prevents development of tolerance and reduction in exercise performance or is associated with a rebound increase in anginal attacks in patients with stable angina pectoris. ■ Design: Multicenter, placebo-controlled, parallelgroup, double-blind, randomized study. ■ Setting: Four university teaching hospitals and five private cardiology outpatient clinics. ■ Patients: 116 patients with stable exertional angina who stopped treadmill exercise because of angina pectoris. ■ Intervention: After stopping all antianginal drugs with the exception of beta-blockers, patients received singleblind placebo for .1 week followed by either 20 mg of IS-5-MN (n = 60 patients) or placebo (n = 62 patients) twice daily at 0800 hours and 1500 hours for 2 weeks. ■ Measurements: Serial symptom-limited exercise tests and patients' diaries recording activity and date, time, and severity of anginal attacks. ■ Results: Compared with placebo recipients, patients receiving IS-5-MN walked significantly longer at 2, 5, and 7 hours after the 0800-hour dose (P < 0.01) and at 2 and 5 hours after the 1500-hour dose (P < 0.01). Before the morning (0800-hour) dose, exercise duration increased by 0.53 minutes in placebo recipients and by 0.85 minutes in those receiving IS-5-MN therapy (P = 0.10). Neither nocturnal nor early-morning anginal attacks increased during IS-5-MN therapy compared with placebo. Headaches occurred in 19 (32%) patients in the IS-5-MN group and in 9 (15%) patients in the placebo group but necessitated discontinuation of treatment in only 2 (3%) patients in the IS-5-MN group. ■ Conclusion: lsosorbide-5-mononitrate, 20 mg twice daily given 7 hours apart, was well tolerated and improved exercise performance for 7 hours after the morning dose and for 5 hours after the afternoon dose without evidence of development of pharmacologic tolerance. No rebound increase in anginal attacks was found.
UR - http://www.scopus.com/inward/record.url?scp=0028097946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028097946&partnerID=8YFLogxK
M3 - Article
C2 - 8093132
AN - SCOPUS:0028097946
VL - 120
SP - 353
EP - 359
JO - Annals of Internal Medicine
JF - Annals of Internal Medicine
SN - 0003-4819
IS - 5
ER -